Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Skin Neoplasms | 40 | 2016 | 159 | 5.640 |
Why?
|
Skin | 24 | 2016 | 174 | 2.310 |
Why?
|
Signal Processing, Computer-Assisted | 2 | 2024 | 61 | 1.800 |
Why?
|
Facial Dermatoses | 9 | 2016 | 10 | 1.760 |
Why?
|
Skin Diseases | 14 | 2013 | 31 | 1.380 |
Why?
|
Humans | 170 | 2024 | 37093 | 1.360 |
Why?
|
Lasers, Solid-State | 7 | 2016 | 13 | 1.350 |
Why?
|
Paraneoplastic Syndromes | 3 | 2013 | 4 | 1.160 |
Why?
|
Hyperpigmentation | 5 | 2015 | 10 | 1.160 |
Why?
|
Female | 113 | 2024 | 20969 | 1.110 |
Why?
|
Regenerative Medicine | 2 | 2022 | 11 | 1.100 |
Why?
|
Male | 89 | 2024 | 20025 | 1.050 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 4 | 2016 | 19 | 1.020 |
Why?
|
Adult | 78 | 2024 | 11712 | 1.010 |
Why?
|
Granuloma | 5 | 2013 | 26 | 1.010 |
Why?
|
Melanoma | 3 | 2015 | 96 | 1.000 |
Why?
|
Hair Follicle | 3 | 2014 | 5 | 0.970 |
Why?
|
Electromyography | 1 | 2024 | 55 | 0.960 |
Why?
|
Head and Neck Neoplasms | 3 | 2016 | 78 | 0.960 |
Why?
|
Hair Diseases | 3 | 2013 | 5 | 0.950 |
Why?
|
Tacrolimus | 3 | 2013 | 10 | 0.920 |
Why?
|
Electroencephalography | 1 | 2024 | 116 | 0.900 |
Why?
|
Mechanical Phenomena | 1 | 2022 | 9 | 0.870 |
Why?
|
Elasticity Imaging Techniques | 1 | 2022 | 9 | 0.870 |
Why?
|
Nevus | 2 | 2012 | 5 | 0.870 |
Why?
|
Foot Dermatoses | 2 | 2014 | 2 | 0.860 |
Why?
|
Dermatitis, Exfoliative | 2 | 2013 | 2 | 0.840 |
Why?
|
Diagnosis, Differential | 34 | 2016 | 217 | 0.830 |
Why?
|
Middle Aged | 64 | 2016 | 10129 | 0.830 |
Why?
|
Glomus Tumor | 2 | 2012 | 2 | 0.820 |
Why?
|
Edema | 3 | 2016 | 23 | 0.820 |
Why?
|
Young Adult | 23 | 2016 | 4268 | 0.800 |
Why?
|
Low Back Pain | 1 | 2022 | 92 | 0.790 |
Why?
|
Dermatologic Agents | 5 | 2015 | 9 | 0.780 |
Why?
|
Adipose Tissue | 2 | 2012 | 177 | 0.780 |
Why?
|
Acrodermatitis | 3 | 2009 | 4 | 0.750 |
Why?
|
Erythema | 5 | 2016 | 10 | 0.750 |
Why?
|
Scalp | 7 | 2013 | 12 | 0.680 |
Why?
|
Skin Diseases, Vesiculobullous | 6 | 2009 | 7 | 0.650 |
Why?
|
Treatment Outcome | 23 | 2016 | 1369 | 0.650 |
Why?
|
Trichophyton | 4 | 2011 | 5 | 0.640 |
Why?
|
Porokeratosis | 4 | 2010 | 4 | 0.590 |
Why?
|
Hamartoma | 3 | 2012 | 6 | 0.590 |
Why?
|
Laser Therapy | 5 | 2011 | 30 | 0.590 |
Why?
|
Skin Ulcer | 2 | 2015 | 5 | 0.590 |
Why?
|
Tinea | 3 | 2011 | 7 | 0.580 |
Why?
|
Carcinoma, Neuroendocrine | 2 | 2014 | 4 | 0.580 |
Why?
|
Skin Aging | 5 | 2014 | 10 | 0.570 |
Why?
|
Granuloma, Foreign-Body | 3 | 2012 | 4 | 0.570 |
Why?
|
Nevus, Pigmented | 3 | 2013 | 5 | 0.570 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 9 | 2013 | 182 | 0.560 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 6 | 2016 | 6 | 0.560 |
Why?
|
Lymphoma, Extranodal NK-T-Cell | 1 | 2016 | 1 | 0.560 |
Why?
|
Hyaluronic Acid | 2 | 2014 | 33 | 0.560 |
Why?
|
Biopsy | 9 | 2016 | 164 | 0.560 |
Why?
|
Immunosuppressive Agents | 3 | 2011 | 76 | 0.540 |
Why?
|
Lichen Planus | 3 | 2011 | 5 | 0.520 |
Why?
|
Xanthogranuloma, Juvenile | 1 | 2015 | 1 | 0.520 |
Why?
|
Acne Vulgaris | 3 | 2011 | 7 | 0.520 |
Why?
|
Aged | 35 | 2016 | 6741 | 0.510 |
Why?
|
Callosities | 1 | 2014 | 1 | 0.510 |
Why?
|
Myxoma | 2 | 2012 | 5 | 0.510 |
Why?
|
Immunocompromised Host | 3 | 2011 | 22 | 0.500 |
Why?
|
Child | 25 | 2016 | 3131 | 0.500 |
Why?
|
Bleomycin | 1 | 2014 | 20 | 0.500 |
Why?
|
Biopsy, Needle | 20 | 2016 | 60 | 0.500 |
Why?
|
Antifungal Agents | 4 | 2011 | 148 | 0.500 |
Why?
|
Immunohistochemistry | 26 | 2016 | 893 | 0.500 |
Why?
|
ACTH Syndrome, Ectopic | 1 | 2014 | 2 | 0.500 |
Why?
|
Thymus Neoplasms | 1 | 2014 | 4 | 0.500 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2014 | 44 | 0.490 |
Why?
|
Acanthoma | 1 | 2014 | 1 | 0.490 |
Why?
|
Keratosis, Seborrheic | 1 | 2014 | 2 | 0.490 |
Why?
|
Dermatitis | 2 | 2015 | 10 | 0.490 |
Why?
|
Drug Resistance, Fungal | 2 | 2011 | 32 | 0.480 |
Why?
|
Movement | 3 | 2024 | 97 | 0.470 |
Why?
|
Dermatitis, Atopic | 1 | 2013 | 12 | 0.470 |
Why?
|
Skin Diseases, Bacterial | 2 | 2010 | 4 | 0.470 |
Why?
|
Lichen Nitidus | 1 | 2013 | 1 | 0.450 |
Why?
|
Penile Diseases | 1 | 2013 | 7 | 0.450 |
Why?
|
Antineoplastic Agents | 5 | 2016 | 803 | 0.450 |
Why?
|
Alopecia | 1 | 2013 | 9 | 0.450 |
Why?
|
Antibodies, Monoclonal | 3 | 2010 | 290 | 0.450 |
Why?
|
Angiomyolipoma | 1 | 2012 | 2 | 0.440 |
Why?
|
Foot Diseases | 1 | 2012 | 2 | 0.440 |
Why?
|
Child, Preschool | 13 | 2015 | 1418 | 0.440 |
Why?
|
Skull | 1 | 2013 | 35 | 0.440 |
Why?
|
Lipomatosis | 1 | 2012 | 1 | 0.440 |
Why?
|
Dextrans | 1 | 2012 | 21 | 0.440 |
Why?
|
Vascular Neoplasms | 2 | 2010 | 2 | 0.430 |
Why?
|
Muscle, Skeletal | 1 | 2015 | 282 | 0.430 |
Why?
|
Prurigo | 1 | 2012 | 2 | 0.430 |
Why?
|
Pigmentation Disorders | 1 | 2012 | 3 | 0.430 |
Why?
|
Retrospective Studies | 19 | 2016 | 2026 | 0.420 |
Why?
|
Dura Mater | 1 | 2012 | 1 | 0.420 |
Why?
|
Neurofibromatosis 1 | 1 | 2012 | 5 | 0.410 |
Why?
|
Molluscum Contagiosum | 1 | 2011 | 2 | 0.410 |
Why?
|
Fasciitis | 2 | 2009 | 3 | 0.410 |
Why?
|
Adolescent | 24 | 2016 | 5363 | 0.400 |
Why?
|
Dermatofibrosarcoma | 1 | 2011 | 1 | 0.390 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2016 | 128 | 0.390 |
Why?
|
Lasers, Gas | 1 | 2011 | 2 | 0.390 |
Why?
|
Punctures | 1 | 2011 | 4 | 0.390 |
Why?
|
Epstein-Barr Virus Infections | 2 | 2012 | 15 | 0.390 |
Why?
|
Vitamin D | 1 | 2013 | 196 | 0.390 |
Why?
|
Fanconi Anemia | 1 | 2011 | 12 | 0.390 |
Why?
|
Aminolevulinic Acid | 1 | 2011 | 8 | 0.390 |
Why?
|
Photochemotherapy | 2 | 2011 | 39 | 0.390 |
Why?
|
Fingers | 1 | 2011 | 20 | 0.380 |
Why?
|
Uterine Neoplasms | 2 | 2009 | 39 | 0.380 |
Why?
|
Mycobacterium Infections | 1 | 2010 | 16 | 0.370 |
Why?
|
Triazoles | 1 | 2011 | 86 | 0.370 |
Why?
|
Hemangioma | 2 | 2007 | 7 | 0.370 |
Why?
|
Mycobacterium | 1 | 2010 | 15 | 0.370 |
Why?
|
Lymphadenitis | 1 | 2010 | 3 | 0.370 |
Why?
|
Pyrimidines | 1 | 2011 | 118 | 0.370 |
Why?
|
Lung Diseases, Interstitial | 1 | 2010 | 11 | 0.370 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 1 | 2010 | 10 | 0.370 |
Why?
|
Amyloidosis | 2 | 2008 | 33 | 0.360 |
Why?
|
Lymphatic Abnormalities | 1 | 2010 | 1 | 0.360 |
Why?
|
Port-Wine Stain | 1 | 2010 | 2 | 0.360 |
Why?
|
Noonan Syndrome | 1 | 2010 | 3 | 0.360 |
Why?
|
Republic of Korea | 6 | 2015 | 107 | 0.340 |
Why?
|
Epithelial Cells | 1 | 2012 | 384 | 0.340 |
Why?
|
Paraproteinemias | 2 | 2008 | 4 | 0.340 |
Why?
|
Carcinoma, Papillary | 1 | 2009 | 11 | 0.330 |
Why?
|
Esophageal Neoplasms | 1 | 2010 | 127 | 0.330 |
Why?
|
Neurofibromatosis 2 | 1 | 2008 | 1 | 0.330 |
Why?
|
Multiple Endocrine Neoplasia Type 2a | 1 | 2008 | 1 | 0.330 |
Why?
|
Cystadenocarcinoma, Serous | 1 | 2009 | 35 | 0.330 |
Why?
|
Eyelid Diseases | 1 | 2008 | 4 | 0.320 |
Why?
|
Purpura | 1 | 2008 | 3 | 0.320 |
Why?
|
Severity of Illness Index | 14 | 2016 | 610 | 0.320 |
Why?
|
Drug Eruptions | 4 | 2015 | 8 | 0.320 |
Why?
|
Knee | 3 | 2009 | 7 | 0.310 |
Why?
|
Eccrine Glands | 5 | 2010 | 6 | 0.310 |
Why?
|
Multiple Myeloma | 1 | 2008 | 39 | 0.310 |
Why?
|
POEMS Syndrome | 1 | 2007 | 1 | 0.300 |
Why?
|
Follow-Up Studies | 13 | 2015 | 974 | 0.300 |
Why?
|
Lymphoma, T-Cell, Peripheral | 2 | 2003 | 4 | 0.290 |
Why?
|
Dermatomycoses | 3 | 2015 | 7 | 0.270 |
Why?
|
Sarcoidosis | 1 | 2006 | 11 | 0.270 |
Why?
|
Risk Assessment | 13 | 2016 | 753 | 0.270 |
Why?
|
Rosacea | 2 | 2016 | 2 | 0.270 |
Why?
|
Prednisolone | 6 | 2012 | 13 | 0.260 |
Why?
|
Electrocardiography | 2 | 2023 | 156 | 0.260 |
Why?
|
Tomography, X-Ray Computed | 3 | 2012 | 214 | 0.250 |
Why?
|
Lipodystrophy | 1 | 2004 | 8 | 0.250 |
Why?
|
Histiocytoma, Benign Fibrous | 3 | 2015 | 5 | 0.250 |
Why?
|
Dermatitis, Allergic Contact | 3 | 2012 | 5 | 0.250 |
Why?
|
Speech Disorders | 1 | 2024 | 3 | 0.250 |
Why?
|
Xanthomatosis | 4 | 2004 | 5 | 0.240 |
Why?
|
Mouth | 1 | 2024 | 45 | 0.240 |
Why?
|
Face | 3 | 2016 | 51 | 0.240 |
Why?
|
Immunoblastic Lymphadenopathy | 1 | 2003 | 1 | 0.230 |
Why?
|
Aged, 80 and over | 12 | 2016 | 2379 | 0.230 |
Why?
|
Respiratory Rate | 1 | 2023 | 11 | 0.230 |
Why?
|
Monitoring, Physiologic | 1 | 2023 | 38 | 0.220 |
Why?
|
Elastic Modulus | 1 | 2022 | 17 | 0.220 |
Why?
|
Tensile Strength | 1 | 2022 | 25 | 0.220 |
Why?
|
Range of Motion, Articular | 1 | 2022 | 31 | 0.220 |
Why?
|
Lumbar Vertebrae | 1 | 2022 | 31 | 0.220 |
Why?
|
Killer Cells, Natural | 4 | 2006 | 92 | 0.210 |
Why?
|
Microscopy, Atomic Force | 1 | 2022 | 60 | 0.210 |
Why?
|
Dilatation, Pathologic | 2 | 2012 | 9 | 0.210 |
Why?
|
Korea | 10 | 2009 | 43 | 0.210 |
Why?
|
Stress, Mechanical | 1 | 2022 | 113 | 0.210 |
Why?
|
Cicatrix | 4 | 2013 | 17 | 0.210 |
Why?
|
Administration, Cutaneous | 2 | 2013 | 43 | 0.210 |
Why?
|
Lupus Erythematosus, Systemic | 3 | 2012 | 155 | 0.210 |
Why?
|
Hair | 2 | 2014 | 20 | 0.200 |
Why?
|
Thigh | 6 | 2015 | 11 | 0.200 |
Why?
|
Tidal Volume | 1 | 2021 | 10 | 0.200 |
Why?
|
Diaphragm | 1 | 2021 | 11 | 0.190 |
Why?
|
Sweat Gland Diseases | 3 | 2008 | 3 | 0.190 |
Why?
|
Injections, Intralesional | 5 | 2014 | 11 | 0.190 |
Why?
|
Subcutaneous Tissue | 3 | 2005 | 5 | 0.190 |
Why?
|
Respiration | 1 | 2021 | 58 | 0.190 |
Why?
|
Glucocorticoids | 5 | 2010 | 86 | 0.190 |
Why?
|
Granuloma Annulare | 3 | 2005 | 3 | 0.180 |
Why?
|
Pseudolymphoma | 3 | 2005 | 5 | 0.180 |
Why?
|
Herpes Zoster | 3 | 2005 | 12 | 0.180 |
Why?
|
Epidermal Growth Factor | 2 | 2015 | 68 | 0.180 |
Why?
|
Nipples | 3 | 2005 | 14 | 0.180 |
Why?
|
Soft Tissue Neoplasms | 3 | 2005 | 15 | 0.170 |
Why?
|
Adenocarcinoma | 3 | 2008 | 251 | 0.170 |
Why?
|
Recurrence | 3 | 2014 | 131 | 0.160 |
Why?
|
Infant, Newborn | 3 | 2015 | 894 | 0.160 |
Why?
|
Lymphatic Metastasis | 3 | 2014 | 65 | 0.160 |
Why?
|
Infant | 10 | 2010 | 1046 | 0.160 |
Why?
|
Motion | 1 | 2017 | 27 | 0.150 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2011 | 30 | 0.150 |
Why?
|
Leg Ulcer | 2 | 2016 | 8 | 0.150 |
Why?
|
Skin Diseases, Vascular | 2 | 2008 | 4 | 0.150 |
Why?
|
Ichthyosis | 3 | 2006 | 4 | 0.150 |
Why?
|
Atrophy | 2 | 2015 | 42 | 0.140 |
Why?
|
Mite Infestations | 1 | 2016 | 3 | 0.140 |
Why?
|
Sweat Gland Neoplasms | 2 | 2006 | 2 | 0.140 |
Why?
|
Lymphoma, Primary Cutaneous Anaplastic Large Cell | 1 | 2016 | 1 | 0.140 |
Why?
|
Cosmetic Techniques | 3 | 2014 | 4 | 0.140 |
Why?
|
Neurilemmoma | 2 | 2009 | 4 | 0.140 |
Why?
|
Histiocytosis | 2 | 2008 | 2 | 0.130 |
Why?
|
Nail Diseases | 1 | 2015 | 3 | 0.130 |
Why?
|
Keratosis | 2 | 2005 | 4 | 0.130 |
Why?
|
Stomach Neoplasms | 2 | 2008 | 195 | 0.130 |
Why?
|
Ultraviolet Rays | 1 | 2016 | 117 | 0.130 |
Why?
|
Facial Neoplasms | 2 | 2007 | 6 | 0.130 |
Why?
|
Nose Diseases | 1 | 2015 | 2 | 0.130 |
Why?
|
Anti-Inflammatory Agents | 4 | 2012 | 149 | 0.130 |
Why?
|
Single-Blind Method | 2 | 2014 | 55 | 0.130 |
Why?
|
Calcinosis | 2 | 2005 | 59 | 0.130 |
Why?
|
Ginsenosides | 1 | 2014 | 4 | 0.130 |
Why?
|
Panax | 1 | 2014 | 7 | 0.130 |
Why?
|
Skin Diseases, Metabolic | 1 | 2014 | 1 | 0.130 |
Why?
|
Mucopolysaccharidosis II | 1 | 2014 | 1 | 0.130 |
Why?
|
Keloid | 2 | 2005 | 3 | 0.120 |
Why?
|
Neck | 5 | 2006 | 22 | 0.120 |
Why?
|
Cushing Syndrome | 1 | 2014 | 5 | 0.120 |
Why?
|
Adrenalectomy | 1 | 2014 | 25 | 0.120 |
Why?
|
Microspheres | 2 | 2012 | 49 | 0.120 |
Why?
|
Pain | 2 | 2014 | 251 | 0.120 |
Why?
|
Sphingosine | 2 | 2005 | 21 | 0.120 |
Why?
|
Neoplasm Staging | 4 | 2016 | 275 | 0.120 |
Why?
|
Keratinocytes | 1 | 2014 | 66 | 0.120 |
Why?
|
Matrix Metalloproteinase 1 | 3 | 2016 | 22 | 0.120 |
Why?
|
Hemangiopericytoma | 2 | 2005 | 2 | 0.120 |
Why?
|
Prognosis | 5 | 2016 | 739 | 0.120 |
Why?
|
Folliculitis | 2 | 2004 | 2 | 0.120 |
Why?
|
Rhinitis, Allergic, Perennial | 1 | 2013 | 5 | 0.120 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2013 | 2 | 0.120 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2013 | 4 | 0.120 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2006 | 39 | 0.120 |
Why?
|
Organ Transplantation | 1 | 2013 | 18 | 0.120 |
Why?
|
Immunoglobulin E | 1 | 2013 | 55 | 0.120 |
Why?
|
Pain Measurement | 1 | 2014 | 171 | 0.120 |
Why?
|
Mice | 2 | 2022 | 5913 | 0.120 |
Why?
|
Administration, Topical | 7 | 2007 | 40 | 0.110 |
Why?
|
Incidence | 3 | 2013 | 922 | 0.110 |
Why?
|
Viscosupplements | 1 | 2012 | 1 | 0.110 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2013 | 178 | 0.110 |
Why?
|
Dapsone | 1 | 2012 | 2 | 0.110 |
Why?
|
Pressure | 1 | 2012 | 43 | 0.110 |
Why?
|
Hair Color | 1 | 2012 | 1 | 0.110 |
Why?
|
Lymphoproliferative Disorders | 1 | 2012 | 10 | 0.110 |
Why?
|
Minocycline | 1 | 2012 | 5 | 0.110 |
Why?
|
Vincristine | 2 | 2010 | 14 | 0.110 |
Why?
|
Gene Expression | 1 | 2016 | 674 | 0.110 |
Why?
|
Fibroblasts | 2 | 2005 | 272 | 0.110 |
Why?
|
Preservatives, Pharmaceutical | 1 | 2012 | 2 | 0.110 |
Why?
|
Cosmetics | 1 | 2012 | 9 | 0.110 |
Why?
|
Nutrition Surveys | 1 | 2013 | 242 | 0.110 |
Why?
|
Chemexfoliation | 1 | 2012 | 1 | 0.110 |
Why?
|
Melanosis | 1 | 2012 | 3 | 0.100 |
Why?
|
Cyclophosphamide | 2 | 2010 | 54 | 0.100 |
Why?
|
Rare Diseases | 2 | 2010 | 13 | 0.100 |
Why?
|
Animals | 5 | 2022 | 15081 | 0.100 |
Why?
|
Scoliosis | 1 | 2012 | 7 | 0.100 |
Why?
|
Forehead | 1 | 2011 | 1 | 0.100 |
Why?
|
Lymphoid Tissue | 1 | 2011 | 18 | 0.100 |
Why?
|
Doxorubicin | 2 | 2010 | 84 | 0.100 |
Why?
|
Sulfonylurea Compounds | 1 | 2011 | 12 | 0.100 |
Why?
|
Liver Neoplasms | 3 | 2005 | 190 | 0.100 |
Why?
|
Amphotericin B | 1 | 2011 | 24 | 0.100 |
Why?
|
Risk Factors | 4 | 2016 | 3562 | 0.100 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2011 | 52 | 0.100 |
Why?
|
Plant Extracts | 1 | 2014 | 286 | 0.100 |
Why?
|
Activating Transcription Factor 3 | 1 | 2011 | 3 | 0.100 |
Why?
|
Sebum | 1 | 2011 | 1 | 0.100 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2009 | 63 | 0.100 |
Why?
|
Stem Cell Transplantation | 1 | 2011 | 31 | 0.100 |
Why?
|
Statistics, Nonparametric | 1 | 2011 | 108 | 0.090 |
Why?
|
Disease-Free Survival | 3 | 2016 | 113 | 0.090 |
Why?
|
Sampling Studies | 4 | 2016 | 61 | 0.090 |
Why?
|
Etoposide | 1 | 2010 | 22 | 0.090 |
Why?
|
Methylprednisolone | 1 | 2010 | 14 | 0.090 |
Why?
|
Cyclosporine | 1 | 2010 | 27 | 0.090 |
Why?
|
Dexamethasone | 1 | 2010 | 45 | 0.090 |
Why?
|
Hidradenitis | 1 | 2010 | 1 | 0.090 |
Why?
|
Liposomes | 1 | 2011 | 118 | 0.090 |
Why?
|
Mycobacterium chelonae | 1 | 2009 | 2 | 0.090 |
Why?
|
Immunocompetence | 1 | 2009 | 8 | 0.090 |
Why?
|
Hypoglycemic Agents | 1 | 2011 | 160 | 0.090 |
Why?
|
Databases, Factual | 3 | 2016 | 291 | 0.090 |
Why?
|
Asthma | 1 | 2013 | 380 | 0.090 |
Why?
|
Carcinoma, Large Cell | 1 | 2009 | 3 | 0.090 |
Why?
|
Neuroendocrine Tumors | 1 | 2009 | 4 | 0.090 |
Why?
|
Hepatitis, Autoimmune | 1 | 2009 | 2 | 0.080 |
Why?
|
Kidney Failure, Chronic | 1 | 2011 | 233 | 0.080 |
Why?
|
Umbilicus | 1 | 2009 | 4 | 0.080 |
Why?
|
Omentum | 1 | 2009 | 5 | 0.080 |
Why?
|
Polyarteritis Nodosa | 1 | 2009 | 4 | 0.080 |
Why?
|
Disability Evaluation | 1 | 2009 | 61 | 0.080 |
Why?
|
Arthralgia | 2 | 2006 | 11 | 0.080 |
Why?
|
Mediastinal Neoplasms | 1 | 2008 | 6 | 0.080 |
Why?
|
Pseudoxanthoma Elasticum | 1 | 2009 | 32 | 0.080 |
Why?
|
Cell Proliferation | 1 | 2014 | 1198 | 0.080 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2009 | 37 | 0.080 |
Why?
|
Hysterectomy | 1 | 2009 | 28 | 0.080 |
Why?
|
Ovariectomy | 1 | 2009 | 105 | 0.080 |
Why?
|
Silver Compounds | 1 | 2008 | 2 | 0.080 |
Why?
|
Osteosarcoma | 1 | 2008 | 26 | 0.080 |
Why?
|
Argyria | 1 | 2008 | 2 | 0.080 |
Why?
|
Hand Dermatoses | 1 | 2008 | 1 | 0.080 |
Why?
|
Hypertrophy | 1 | 2008 | 32 | 0.080 |
Why?
|
Crohn Disease | 1 | 2009 | 63 | 0.080 |
Why?
|
Hedgehogs | 1 | 2008 | 3 | 0.080 |
Why?
|
Bence Jones Protein | 1 | 2008 | 1 | 0.080 |
Why?
|
Immunoglobulin lambda-Chains | 1 | 2008 | 3 | 0.080 |
Why?
|
Forearm | 2 | 2005 | 8 | 0.080 |
Why?
|
Eyelids | 1 | 2008 | 3 | 0.080 |
Why?
|
Zinc | 1 | 2009 | 128 | 0.080 |
Why?
|
Hair Preparations | 1 | 2008 | 2 | 0.080 |
Why?
|
Abdomen | 2 | 2005 | 12 | 0.080 |
Why?
|
Itraconazole | 2 | 2011 | 12 | 0.080 |
Why?
|
Survival Rate | 3 | 2016 | 311 | 0.080 |
Why?
|
Collagen | 2 | 2009 | 172 | 0.080 |
Why?
|
Dietary Supplements | 1 | 2009 | 208 | 0.070 |
Why?
|
Carcinoma, Signet Ring Cell | 1 | 2007 | 4 | 0.070 |
Why?
|
Aminoquinolines | 1 | 2007 | 14 | 0.070 |
Why?
|
Brain Neoplasms | 2 | 2005 | 111 | 0.070 |
Why?
|
Picibanil | 1 | 2006 | 2 | 0.070 |
Why?
|
Lymphangioma | 1 | 2006 | 5 | 0.070 |
Why?
|
Vulvar Neoplasms | 1 | 2006 | 12 | 0.070 |
Why?
|
Histiocytic Necrotizing Lymphadenitis | 1 | 2006 | 4 | 0.070 |
Why?
|
Sweet Syndrome | 1 | 2006 | 1 | 0.070 |
Why?
|
Neoplasms, Connective and Soft Tissue | 1 | 2006 | 1 | 0.070 |
Why?
|
Myelodysplastic Syndromes | 1 | 2006 | 6 | 0.070 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2005 | 121 | 0.070 |
Why?
|
Foot | 1 | 2006 | 10 | 0.070 |
Why?
|
Hidrocystoma | 1 | 2006 | 1 | 0.070 |
Why?
|
Bile Duct Neoplasms | 1 | 2006 | 3 | 0.070 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 2006 | 4 | 0.070 |
Why?
|
Lung Neoplasms | 3 | 2009 | 358 | 0.070 |
Why?
|
Leg Dermatoses | 2 | 2004 | 2 | 0.070 |
Why?
|
Cholangiocarcinoma | 1 | 2006 | 6 | 0.070 |
Why?
|
Adjuvants, Immunologic | 1 | 2007 | 107 | 0.070 |
Why?
|
Leg | 2 | 2016 | 19 | 0.070 |
Why?
|
Piroxicam | 1 | 2005 | 2 | 0.070 |
Why?
|
Perfume | 1 | 2005 | 3 | 0.070 |
Why?
|
Peptidyl-Dipeptidase A | 1 | 2006 | 31 | 0.070 |
Why?
|
Scleroderma, Systemic | 1 | 2006 | 11 | 0.070 |
Why?
|
Diabetes Mellitus | 1 | 2011 | 485 | 0.070 |
Why?
|
Arthrogryposis | 1 | 2005 | 4 | 0.070 |
Why?
|
Anti-Allergic Agents | 1 | 2005 | 2 | 0.070 |
Why?
|
Mastocytosis, Cutaneous | 1 | 2005 | 1 | 0.070 |
Why?
|
Cholestasis | 1 | 2005 | 9 | 0.070 |
Why?
|
Cystadenocarcinoma, Papillary | 1 | 2005 | 3 | 0.070 |
Why?
|
Elastic Tissue | 1 | 2005 | 7 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2005 | 14 | 0.070 |
Why?
|
Diet | 1 | 2012 | 801 | 0.070 |
Why?
|
Hypertrichosis | 1 | 2005 | 1 | 0.070 |
Why?
|
Radiation Injuries | 1 | 2005 | 22 | 0.070 |
Why?
|
Abnormalities, Multiple | 1 | 2005 | 36 | 0.070 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2004 | 88 | 0.070 |
Why?
|
Exanthema | 1 | 2005 | 10 | 0.070 |
Why?
|
Breast Neoplasms | 3 | 2005 | 1502 | 0.070 |
Why?
|
Angiolipoma | 1 | 2005 | 1 | 0.070 |
Why?
|
Wrist | 1 | 2005 | 6 | 0.070 |
Why?
|
DNA-Binding Proteins | 1 | 2009 | 539 | 0.070 |
Why?
|
Genital Neoplasms, Male | 1 | 2005 | 2 | 0.070 |
Why?
|
Kidney Tubules | 1 | 2005 | 33 | 0.060 |
Why?
|
Myoepithelioma | 1 | 2005 | 1 | 0.060 |
Why?
|
Burns | 1 | 2005 | 7 | 0.060 |
Why?
|
Fatigue | 1 | 2006 | 83 | 0.060 |
Why?
|
Parotid Neoplasms | 1 | 2005 | 2 | 0.060 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2005 | 14 | 0.060 |
Why?
|
Rectal Neoplasms | 1 | 2005 | 12 | 0.060 |
Why?
|
Vibrio Infections | 1 | 2005 | 4 | 0.060 |
Why?
|
Drugs, Chinese Herbal | 1 | 2005 | 19 | 0.060 |
Why?
|
Stevens-Johnson Syndrome | 1 | 2005 | 3 | 0.060 |
Why?
|
Vibrio vulnificus | 1 | 2005 | 5 | 0.060 |
Why?
|
Calcitriol | 1 | 2005 | 31 | 0.060 |
Why?
|
Acanthosis Nigricans | 1 | 2005 | 10 | 0.060 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2008 | 277 | 0.060 |
Why?
|
Neuroma | 1 | 2004 | 1 | 0.060 |
Why?
|
Bacteremia | 1 | 2005 | 30 | 0.060 |
Why?
|
Candidiasis | 1 | 2005 | 84 | 0.060 |
Why?
|
Fat Necrosis | 1 | 2004 | 3 | 0.060 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2004 | 18 | 0.060 |
Why?
|
Granuloma, Pyogenic | 1 | 2004 | 2 | 0.060 |
Why?
|
Prostheses and Implants | 1 | 2004 | 15 | 0.060 |
Why?
|
Angiolymphoid Hyperplasia with Eosinophilia | 1 | 2004 | 1 | 0.060 |
Why?
|
Polymethyl Methacrylate | 1 | 2004 | 14 | 0.060 |
Why?
|
Proportional Hazards Models | 2 | 2016 | 441 | 0.060 |
Why?
|
Vasculitis | 1 | 2004 | 4 | 0.060 |
Why?
|
Mucinosis, Follicular | 1 | 2004 | 1 | 0.060 |
Why?
|
Silicone Gels | 1 | 2004 | 1 | 0.060 |
Why?
|
Histiocytosis, Non-Langerhans-Cell | 1 | 2004 | 2 | 0.060 |
Why?
|
Chromosomes, Human, Pair 5 | 1 | 2004 | 10 | 0.060 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 2004 | 9 | 0.060 |
Why?
|
Ketoprofen | 1 | 2003 | 2 | 0.060 |
Why?
|
Palliative Care | 1 | 2004 | 49 | 0.060 |
Why?
|
Sarcoma | 1 | 2004 | 10 | 0.060 |
Why?
|
2-Aminopurine | 1 | 2003 | 9 | 0.060 |
Why?
|
Methotrexate | 1 | 2004 | 23 | 0.060 |
Why?
|
Eosinophilia | 1 | 2004 | 18 | 0.060 |
Why?
|
Dermatitis Herpetiformis | 1 | 2003 | 1 | 0.060 |
Why?
|
Angiokeratoma | 1 | 2003 | 2 | 0.060 |
Why?
|
Antirheumatic Agents | 1 | 2004 | 31 | 0.060 |
Why?
|
Quinazolines | 1 | 2004 | 33 | 0.060 |
Why?
|
Chromosomes, Human, Pair 22 | 1 | 2004 | 39 | 0.060 |
Why?
|
Psoriasis | 1 | 2003 | 17 | 0.060 |
Why?
|
Necrobiotic Disorders | 1 | 2003 | 1 | 0.060 |
Why?
|
Kidney Diseases | 1 | 2005 | 167 | 0.060 |
Why?
|
Survival Analysis | 2 | 2015 | 325 | 0.060 |
Why?
|
Skin Abnormalities | 1 | 2003 | 1 | 0.060 |
Why?
|
Collagen Type I | 2 | 2016 | 30 | 0.060 |
Why?
|
Biocompatible Materials | 1 | 2004 | 76 | 0.060 |
Why?
|
Hemangioma, Capillary | 1 | 2003 | 2 | 0.060 |
Why?
|
Dermatomyositis | 1 | 2003 | 7 | 0.060 |
Why?
|
Neoplasm Invasiveness | 2 | 2015 | 251 | 0.060 |
Why?
|
Chromosome Aberrations | 1 | 2004 | 60 | 0.060 |
Why?
|
Malassezia | 1 | 2003 | 5 | 0.060 |
Why?
|
Proteoglycans | 1 | 2003 | 47 | 0.050 |
Why?
|
Scabies | 1 | 2002 | 1 | 0.050 |
Why?
|
Urticaria Pigmentosa | 1 | 2002 | 1 | 0.050 |
Why?
|
Antigens | 1 | 2003 | 56 | 0.050 |
Why?
|
Tinea Capitis | 1 | 2002 | 1 | 0.050 |
Why?
|
Pancreatic Neoplasms | 1 | 2004 | 111 | 0.050 |
Why?
|
Diagnostic Errors | 1 | 2002 | 20 | 0.050 |
Why?
|
Diaper Rash | 1 | 2002 | 1 | 0.050 |
Why?
|
Myxedema | 1 | 2002 | 1 | 0.050 |
Why?
|
Ornithine Carbamoyltransferase Deficiency Disease | 1 | 2002 | 2 | 0.050 |
Why?
|
Sebaceous Gland Diseases | 1 | 2002 | 1 | 0.050 |
Why?
|
Carcinoma, Basal Cell | 2 | 2013 | 20 | 0.050 |
Why?
|
Epidermal Cyst | 1 | 2002 | 1 | 0.050 |
Why?
|
Granular Cell Tumor | 1 | 2002 | 1 | 0.050 |
Why?
|
Lymphoma, T-Cell | 1 | 2002 | 28 | 0.050 |
Why?
|
Erythema Nodosum | 1 | 2002 | 2 | 0.050 |
Why?
|
Lymphocytes | 1 | 2003 | 118 | 0.050 |
Why?
|
Tattooing | 1 | 2002 | 7 | 0.050 |
Why?
|
Pregnancy Complications | 1 | 2003 | 126 | 0.050 |
Why?
|
Plant Preparations | 1 | 2002 | 27 | 0.050 |
Why?
|
Syndrome | 3 | 2006 | 74 | 0.050 |
Why?
|
Lasers | 1 | 2002 | 65 | 0.050 |
Why?
|
Enzyme Inhibitors | 1 | 2004 | 433 | 0.050 |
Why?
|
Carcinoma | 1 | 2002 | 96 | 0.050 |
Why?
|
Respiratory Sounds | 1 | 2021 | 11 | 0.050 |
Why?
|
Phytotherapy | 1 | 2002 | 81 | 0.050 |
Why?
|
Leiomyoma | 1 | 2002 | 30 | 0.050 |
Why?
|
Acoustics | 1 | 2021 | 15 | 0.050 |
Why?
|
Kidney Transplantation | 1 | 2002 | 86 | 0.050 |
Why?
|
Time Factors | 2 | 2016 | 1742 | 0.050 |
Why?
|
Lymph Nodes | 2 | 2016 | 67 | 0.050 |
Why?
|
Fatal Outcome | 3 | 2009 | 40 | 0.050 |
Why?
|
RNA, Messenger | 2 | 2016 | 1207 | 0.050 |
Why?
|
Cell Nucleus | 1 | 2002 | 366 | 0.040 |
Why?
|
Patch Tests | 2 | 2012 | 5 | 0.040 |
Why?
|
Apoptosis | 2 | 2004 | 1398 | 0.040 |
Why?
|
Caustics | 2 | 2012 | 2 | 0.040 |
Why?
|
Trichloroacetic Acid | 2 | 2012 | 2 | 0.040 |
Why?
|
Age Distribution | 2 | 2013 | 225 | 0.040 |
Why?
|
Sex Distribution | 2 | 2013 | 215 | 0.040 |
Why?
|
Disease Progression | 2 | 2016 | 601 | 0.040 |
Why?
|
Steroids | 2 | 2010 | 43 | 0.040 |
Why?
|
Injections, Subcutaneous | 2 | 2009 | 33 | 0.040 |
Why?
|
Sex Factors | 2 | 2015 | 898 | 0.040 |
Why?
|
Mites | 1 | 2016 | 8 | 0.030 |
Why?
|
Collagen Type II | 1 | 2016 | 3 | 0.030 |
Why?
|
Tissue Inhibitor of Metalloproteinase-2 | 1 | 2016 | 5 | 0.030 |
Why?
|
Natural Killer T-Cells | 1 | 2016 | 9 | 0.030 |
Why?
|
Mice, Hairless | 1 | 2016 | 7 | 0.030 |
Why?
|
Tissue Inhibitor of Metalloproteinase-1 | 1 | 2016 | 14 | 0.030 |
Why?
|
Erythema Multiforme | 1 | 2015 | 1 | 0.030 |
Why?
|
Parakeratosis | 1 | 2015 | 1 | 0.030 |
Why?
|
Lichenoid Eruptions | 1 | 2015 | 1 | 0.030 |
Why?
|
Matrix Metalloproteinase 3 | 1 | 2016 | 14 | 0.030 |
Why?
|
Platelet-Derived Growth Factor | 1 | 2016 | 26 | 0.030 |
Why?
|
Arm | 2 | 2006 | 28 | 0.030 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2016 | 26 | 0.030 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2016 | 43 | 0.030 |
Why?
|
Toes | 2 | 2006 | 6 | 0.030 |
Why?
|
Fever | 2 | 2006 | 57 | 0.030 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2016 | 90 | 0.030 |
Why?
|
Lentigo | 1 | 2015 | 1 | 0.030 |
Why?
|
Water Loss, Insensible | 1 | 2015 | 1 | 0.030 |
Why?
|
Transforming Growth Factor beta1 | 1 | 2016 | 93 | 0.030 |
Why?
|
Iduronate Sulfatase | 1 | 2014 | 1 | 0.030 |
Why?
|
Enzyme Replacement Therapy | 1 | 2014 | 1 | 0.030 |
Why?
|
Dihydrotestosterone | 1 | 2014 | 29 | 0.030 |
Why?
|
Injections | 1 | 2014 | 35 | 0.030 |
Why?
|
Buttocks | 2 | 2005 | 2 | 0.030 |
Why?
|
Keratins | 2 | 2005 | 25 | 0.030 |
Why?
|
Vimentin | 2 | 2005 | 37 | 0.030 |
Why?
|
Triamcinolone | 2 | 2004 | 2 | 0.030 |
Why?
|
Ceramides | 2 | 2005 | 42 | 0.030 |
Why?
|
Base Sequence | 2 | 2008 | 997 | 0.030 |
Why?
|
Sarcoma, Kaposi | 1 | 2013 | 20 | 0.030 |
Why?
|
Necrosis | 2 | 2005 | 49 | 0.030 |
Why?
|
S100 Proteins | 2 | 2005 | 12 | 0.030 |
Why?
|
Receptors, Androgen | 1 | 2014 | 126 | 0.030 |
Why?
|
Administration, Oral | 2 | 2005 | 224 | 0.030 |
Why?
|
Tissue Donors | 1 | 2013 | 44 | 0.030 |
Why?
|
MAP Kinase Signaling System | 1 | 2014 | 169 | 0.030 |
Why?
|
Molecular Sequence Data | 2 | 2008 | 1568 | 0.030 |
Why?
|
Recombinant Proteins | 1 | 2014 | 515 | 0.030 |
Why?
|
Hydroa Vacciniforme | 1 | 2012 | 1 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2015 | 1039 | 0.030 |
Why?
|
Benzalkonium Compounds | 1 | 2012 | 1 | 0.030 |
Why?
|
Chlorphenesin | 1 | 2012 | 1 | 0.030 |
Why?
|
Immunophenotyping | 2 | 2002 | 57 | 0.030 |
Why?
|
Thiazoles | 1 | 2012 | 74 | 0.030 |
Why?
|
Age Factors | 1 | 2015 | 1033 | 0.020 |
Why?
|
Phosphorylation | 1 | 2014 | 928 | 0.020 |
Why?
|
Bowen's Disease | 1 | 2011 | 4 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 2012 | 145 | 0.020 |
Why?
|
Cohort Studies | 1 | 2015 | 1492 | 0.020 |
Why?
|
Elastin | 1 | 2010 | 40 | 0.020 |
Why?
|
Cells, Cultured | 2 | 2005 | 1518 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 2010 | 189 | 0.020 |
Why?
|
Clarithromycin | 1 | 2009 | 8 | 0.020 |
Why?
|
Microscopy, Confocal | 1 | 2010 | 218 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2014 | 1609 | 0.020 |
Why?
|
Genes, Recessive | 1 | 2009 | 7 | 0.020 |
Why?
|
Skin Physiological Phenomena | 1 | 2009 | 11 | 0.020 |
Why?
|
Antigen-Antibody Complex | 1 | 2009 | 19 | 0.020 |
Why?
|
Triamcinolone Acetonide | 1 | 2008 | 2 | 0.020 |
Why?
|
Activities of Daily Living | 1 | 2009 | 105 | 0.020 |
Why?
|
Colloids | 1 | 2008 | 17 | 0.020 |
Why?
|
Animals, Domestic | 1 | 2008 | 8 | 0.020 |
Why?
|
Arthritis, Rheumatoid | 1 | 2008 | 43 | 0.020 |
Why?
|
Program Development | 1 | 2009 | 233 | 0.020 |
Why?
|
Gels | 1 | 2008 | 42 | 0.020 |
Why?
|
Filtration | 1 | 2007 | 14 | 0.020 |
Why?
|
Sclerotherapy | 1 | 2006 | 3 | 0.020 |
Why?
|
Anal Canal | 1 | 2006 | 30 | 0.020 |
Why?
|
Lymphatic Diseases | 1 | 2006 | 7 | 0.020 |
Why?
|
Lipoma | 1 | 2006 | 4 | 0.020 |
Why?
|
Anti-Bacterial Agents | 1 | 2009 | 352 | 0.020 |
Why?
|
Atropine | 1 | 2006 | 13 | 0.020 |
Why?
|
Leukocyte Count | 1 | 2006 | 77 | 0.020 |
Why?
|
Mastectomy, Radical | 1 | 2005 | 1 | 0.020 |
Why?
|
Norisoprenoids | 1 | 2005 | 2 | 0.020 |
Why?
|
Pentanols | 1 | 2005 | 3 | 0.020 |
Why?
|
Ankle Injuries | 1 | 2005 | 3 | 0.020 |
Why?
|
Propanols | 1 | 2005 | 5 | 0.020 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2005 | 16 | 0.020 |
Why?
|
Cyclohexenes | 1 | 2005 | 4 | 0.020 |
Why?
|
Telangiectasis | 1 | 2005 | 1 | 0.020 |
Why?
|
Plant Oils | 1 | 2005 | 18 | 0.020 |
Why?
|
Cyclopentanes | 1 | 2005 | 21 | 0.020 |
Why?
|
Radiation Dosage | 1 | 2005 | 37 | 0.020 |
Why?
|
Neoplasms, Second Primary | 1 | 2005 | 13 | 0.020 |
Why?
|
Hemoglobins | 1 | 2006 | 107 | 0.020 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2005 | 18 | 0.020 |
Why?
|
Sesquiterpenes | 1 | 2005 | 32 | 0.020 |
Why?
|
Pedigree | 1 | 2005 | 79 | 0.020 |
Why?
|
Neutropenia | 1 | 2005 | 18 | 0.020 |
Why?
|
Cryotherapy | 1 | 2005 | 9 | 0.020 |
Why?
|
Scrotum | 1 | 2005 | 4 | 0.020 |
Why?
|
Aldehydes | 1 | 2005 | 69 | 0.020 |
Why?
|
Shoulder | 1 | 2005 | 9 | 0.020 |
Why?
|
Allergens | 1 | 2005 | 63 | 0.020 |
Why?
|
Bone Neoplasms | 1 | 2005 | 45 | 0.020 |
Why?
|
Penile Neoplasms | 1 | 2005 | 14 | 0.020 |
Why?
|
Mast Cells | 1 | 2005 | 81 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2006 | 149 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2005 | 108 | 0.020 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2005 | 19 | 0.020 |
Why?
|
Pancreatic Function Tests | 1 | 2004 | 1 | 0.020 |
Why?
|
Ossification, Heterotopic | 1 | 2004 | 1 | 0.020 |
Why?
|
Wound Healing | 1 | 2005 | 70 | 0.020 |
Why?
|
Actins | 1 | 2005 | 148 | 0.020 |
Why?
|
Hand | 1 | 2004 | 31 | 0.020 |
Why?
|
Paronychia | 1 | 2004 | 1 | 0.010 |
Why?
|
Acneiform Eruptions | 1 | 2004 | 1 | 0.010 |
Why?
|
Spectral Karyotyping | 1 | 2004 | 2 | 0.010 |
Why?
|
Urticaria | 1 | 2004 | 5 | 0.010 |
Why?
|
Antigens, CD34 | 1 | 2004 | 19 | 0.010 |
Why?
|
Injections, Intramuscular | 1 | 2003 | 20 | 0.010 |
Why?
|
Transcription Factors | 1 | 2009 | 681 | 0.010 |
Why?
|
Prednisone | 1 | 2003 | 27 | 0.010 |
Why?
|
Nucleic Acid Hybridization | 1 | 2004 | 69 | 0.010 |
Why?
|
Cervical Vertebrae | 1 | 2003 | 15 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2004 | 143 | 0.010 |
Why?
|
Isotretinoin | 1 | 2003 | 4 | 0.010 |
Why?
|
Keratolytic Agents | 1 | 2003 | 3 | 0.010 |
Why?
|
Lower Extremity | 1 | 2004 | 33 | 0.010 |
Why?
|
Pregnancy Trimester, Second | 1 | 2003 | 16 | 0.010 |
Why?
|
DNA, Neoplasm | 1 | 2004 | 92 | 0.010 |
Why?
|
Mucinoses | 1 | 2003 | 1 | 0.010 |
Why?
|
Reference Values | 1 | 2004 | 212 | 0.010 |
Why?
|
Connective Tissue | 1 | 2003 | 9 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2003 | 148 | 0.010 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 1 | 2003 | 21 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2004 | 227 | 0.010 |
Why?
|
In Situ Nick-End Labeling | 1 | 2003 | 133 | 0.010 |
Why?
|
Ketoconazole | 1 | 2003 | 7 | 0.010 |
Why?
|
World Health Organization | 1 | 2003 | 31 | 0.010 |
Why?
|
Cell Division | 1 | 2004 | 307 | 0.010 |
Why?
|
Toluidines | 1 | 2002 | 4 | 0.010 |
Why?
|
Europe | 1 | 2003 | 101 | 0.010 |
Why?
|
Antigens, CD | 1 | 2003 | 121 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2004 | 173 | 0.010 |
Why?
|
Sodium Benzoate | 1 | 2002 | 1 | 0.010 |
Why?
|
Thyroid Diseases | 1 | 2002 | 4 | 0.010 |
Why?
|
Diet, Protein-Restricted | 1 | 2002 | 6 | 0.010 |
Why?
|
Peritoneal Dialysis | 1 | 2002 | 9 | 0.010 |
Why?
|
Citrulline | 1 | 2002 | 10 | 0.010 |
Why?
|
Neutrophils | 1 | 2003 | 131 | 0.010 |
Why?
|
Sebaceous Glands | 1 | 2002 | 3 | 0.010 |
Why?
|
Receptors, Antigen, T-Cell, gamma-delta | 1 | 2002 | 16 | 0.010 |
Why?
|
Treatment Refusal | 1 | 2002 | 20 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2005 | 481 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2004 | 448 | 0.010 |
Why?
|
In Situ Hybridization | 1 | 2002 | 129 | 0.010 |
Why?
|
DNA Nucleotidylexotransferase | 1 | 2002 | 5 | 0.010 |
Why?
|
Antiviral Agents | 1 | 2003 | 157 | 0.010 |
Why?
|
Remission, Spontaneous | 1 | 2002 | 2 | 0.010 |
Why?
|
Coma | 1 | 2002 | 4 | 0.010 |
Why?
|
Ankle | 1 | 2002 | 4 | 0.010 |
Why?
|
Hyperplasia | 1 | 2002 | 38 | 0.010 |
Why?
|
Glasgow Coma Scale | 1 | 2002 | 18 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2004 | 562 | 0.010 |
Why?
|
Mastectomy | 1 | 2002 | 15 | 0.010 |
Why?
|
Arginine | 1 | 2002 | 73 | 0.010 |
Why?
|
Abortion, Induced | 1 | 2003 | 85 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2004 | 1130 | 0.010 |
Why?
|
Cell Survival | 1 | 2004 | 864 | 0.010 |
Why?
|
Genotype | 1 | 2002 | 730 | 0.010 |
Why?
|
Pregnancy | 1 | 2003 | 1549 | 0.010 |
Why?
|
Signal Transduction | 1 | 2004 | 1908 | 0.010 |
Why?
|